The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

The fight against obstructive sleep apnea (OSA) has taken a monumental leap forward. For the first time, the U.S. Food and ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

Without insurance coverage, Zepbound costs $1,060 per month ... like reducing heart risks. The FDA approval for sleep apnea ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Sleep apnea can cause a host of health problems, including the inability to lose weight. The FDA has approved Zepbound, a popular weight loss drug, for the treatment of moderate-to-severe ...